Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00491751 · ClinicalTrials.gov registry record · Phase 1
Clinical Utility of Endothelial Dysfunction in PAD
A Phase 1 study, sponsored by Boston University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT00491751 is a Phase 1 study that was terminated before completion, run by Boston University. The registered enrollment target is 108 participants.
The verdict
NCT00491751, a Phase 1 study, was terminated before completion, sponsored by Boston University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
This study will seek to determine whether non-invasive measures of endothelial function have utility as surrogate markers of cardiovascular risk in patients with peripheral arterial disease undergoing vascular surgery. Measurements of endothelial function will be made before and after initiation of atorvastatin, ascorbic acid, or placebo therapy during the pre-operative period. We will then examine cardiovascular events following surgery. We hypothesize that patients who have no improvement in endothelial function will have increased cardiovascular risk compared to patients with improvement in endothelial function.
Interventions
- DRUG Placebo
- DRUG ascorbic acid
- DRUG atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2004-05 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00491751
The ClinicalTrials.gov registry entry for NCT00491751 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00491751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00491751 about?
NCT00491751 is a clinical study titled "Clinical Utility of Endothelial Dysfunction in PAD". This study will seek to determine whether non-invasive measures of endothelial function have utility as surrogate markers of cardiovascular risk in patients with peripheral arterial disease undergoing vascular surgery. Measurements of endothelial function will be made before and after initiation of ...
What is the current status of trial NCT00491751?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2004-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00491751?
The interventions under investigation include: Placebo (DRUG), ascorbic acid (DRUG), atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00491751?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.